One of the UK’s most promising medtech start-ups, Owlstone Medical has been given a major boost by GSK’s decision to include its technology in a major clinical trial programme.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
